Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

Biogen (BIIB) PT Raised to $400 at Oppenheimer

January 26, 2018 6:46 AM EST

Oppenheimer raised its price target on Biogen (NASDAQ: BIIB) to $400.00 (from $380.00) while maintaining a Outperform rating.

Analyst Jay Olson commented, "BIIB shares outperformed yesterday (+2.1% vs. NBI +0.7% and S&P 500 +0.1%) on strong 4Q17 financial results and confidence expressed by management regarding execution on key... More

Biogen (BIIB) PT Raised to $403 at BMO Capital on 4Q Report; '2018 Guidance Above Street With Room to Grow'

January 25, 2018 3:48 PM EST

BMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $403.00 (from $394.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.

Analyst M. Ian Somaiya notes a positive outlook on the shares, as the company reported fourth quarter revenues above... More

Biogen (BIIB) PT Raised to $408 at Cowen

January 25, 2018 1:12 PM EST

Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.

Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.

... More